These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22320349)

  • 1. Investigation of the haemodynamic effects of exenatide in healthy male subjects.
    Mendis B; Simpson E; MacDonald I; Mansell P
    Br J Clin Pharmacol; 2012 Sep; 74(3):437-44. PubMed ID: 22320349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of glucagon-like peptide-1, GLP-1
    Bremholm L; Andersen UB; Hornum M; Hilsted L; Veedfald S; Hartmann B; Holst JJ
    Physiol Rep; 2017 Feb; 5(4):. PubMed ID: 28235974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
    Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.
    Smits MM; Muskiet MH; Tonneijck L; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Br J Clin Pharmacol; 2016 Apr; 81(4):613-20. PubMed ID: 26609792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.
    Gill A; Hoogwerf BJ; Burger J; Bruce S; Macconell L; Yan P; Braun D; Giaconia J; Malone J
    Cardiovasc Diabetol; 2010 Jan; 9():6. PubMed ID: 20109208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.
    Kelly AS; Rudser KD; Nathan BM; Fox CK; Metzig AM; Coombes BJ; Fitch AK; Bomberg EM; Abuzzahab MJ
    JAMA Pediatr; 2013 Apr; 167(4):355-60. PubMed ID: 23380890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL
    Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects.
    Linnebjerg H; Seger M; Kothare PA; Hunt T; Wolka AM; Mitchell MI
    Int J Clin Pharmacol Ther; 2011 Oct; 49(10):594-604. PubMed ID: 21961484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
    Keller J; Trautmann ME; Haber H; Tham LS; Hunt T; Mace K; Linnebjerg H
    Regul Pept; 2012 Nov; 179(1-3):77-83. PubMed ID: 22960288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.
    Nathanson D; Ullman B; Löfström U; Hedman A; Frick M; Sjöholm A; Nyström T
    Diabetologia; 2012 Apr; 55(4):926-35. PubMed ID: 22246377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise.
    Khoo EY; Wallis J; Tsintzas K; Macdonald IA; Mansell P
    Diabetologia; 2010 Jan; 53(1):139-43. PubMed ID: 19898831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.
    Smits MM; Muskiet MH; Tonneijck L; Kramer MH; Diamant M; van Raalte DH; Serné EH
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1538-43. PubMed ID: 25908765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
    Dandona P; Chaudhuri A; Dhindsa S
    Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension.
    Linnebjerg H; Kothare P; Park S; Mace K; Mitchell M
    Int J Clin Pharmacol Ther; 2009 Nov; 47(11):651-8. PubMed ID: 19840529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
    Christensen M; Knop FK
    Curr Diab Rep; 2010 Apr; 10(2):124-32. PubMed ID: 20425571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
    Gejl M; Søndergaard HM; Stecher C; Bibby BM; Møller N; Bøtker HE; Hansen SB; Gjedde A; Rungby J; Brock B
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1165-9. PubMed ID: 22544917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.